Company intelligence / Profile preview

Sumitomo Corporation

Chiyoda-ku, Tokyo, Japanlinkedin.com ↗

Ownership: Public · 8053
Employees: ~81288
Development stage: Commercial

Overview

Sumitomo Corporation provides comprehensive upstream and downstream support to the pharmaceutical industry globally through its group companies. It supplies research materials such as antibodies, nucleic acids, gene vectors, iPS cell-related products and offers licensing/intermediation services including CRISPR/Cas9 technology licensing in Japan. It does not have its own clinical pipeline but enables drug discovery/development by others.

Therapeutic areas: Other
Modalities: AntibodyNucleic acidCell therapy materialsSmall molecule intermediates
Industry: Drug Discovery Services

Partnerships

Acts as agent/licensee for CRISPR/Cas9 patents in Japancollaborates with global biotech/pharma firms on supply/distribution/licensing/research alliances via SPI/SPE/SPC

Beyond the preview

Go deeper on Sumitomo Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sumitomo Corporation.

Explore the full profile